-
Signature
-
/s/ Avraham S. Adler, Attorney-in-Fact
-
Issuer symbol
-
PTCT
-
Transactions as of
-
03 Oct 2025
-
Transactions value $
-
-$772,690
-
Form type
-
4
-
Filing time
-
07 Oct 2025, 17:20:15 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Reeve Emma |
Director |
C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN |
/s/ Avraham S. Adler, Attorney-in-Fact |
07 Oct 2025 |
0001680329 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$394,200 |
+10,000 |
+96.8% |
$39.42 |
20,332 |
03 Oct 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$197,092 |
-3,028 |
-14.9% |
$65.09 |
17,304 |
03 Oct 2025 |
Direct |
F1, F2 |
| transaction |
PTCT |
Common Stock |
Sale |
-$303,419 |
-4,591 |
-26.5% |
$66.09 |
12,713 |
03 Oct 2025 |
Direct |
F1, F3 |
| transaction |
PTCT |
Common Stock |
Sale |
-$159,217 |
-2,381 |
-18.7% |
$66.87 |
10,332 |
03 Oct 2025 |
Direct |
F1, F4 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$228,234 |
+6,912 |
+66.9% |
$33.02 |
17,244 |
03 Oct 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$140,638 |
-2,163 |
-12.5% |
$65.02 |
15,081 |
03 Oct 2025 |
Direct |
F1, F5 |
| transaction |
PTCT |
Common Stock |
Sale |
-$208,180 |
-3,149 |
-20.9% |
$66.11 |
11,932 |
03 Oct 2025 |
Direct |
F1, F6 |
| transaction |
PTCT |
Common Stock |
Sale |
-$107,088 |
-1,600 |
-13.4% |
$66.93 |
10,332 |
03 Oct 2025 |
Direct |
F1, F7 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$290,899 |
+8,650 |
+83.7% |
$33.63 |
18,982 |
03 Oct 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$177,521 |
-2,729 |
-14.4% |
$65.05 |
16,253 |
03 Oct 2025 |
Direct |
F1, F8 |
| transaction |
PTCT |
Common Stock |
Sale |
-$266,845 |
-4,037 |
-24.8% |
$66.10 |
12,216 |
03 Oct 2025 |
Direct |
F1, F9 |
| transaction |
PTCT |
Common Stock |
Sale |
-$126,020 |
-1,884 |
-15.4% |
$66.89 |
10,332 |
03 Oct 2025 |
Direct |
F1, F10 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-10,000 |
-100% |
$0.000000 |
0 |
03 Oct 2025 |
Common Stock |
10,000 |
$33.63 |
Direct |
F1, F11 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-6,912 |
-100% |
$0.000000 |
0 |
03 Oct 2025 |
Common Stock |
6,912 |
$33.02 |
Direct |
F1, F11 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-8,650 |
-100% |
$0.000000 |
0 |
03 Oct 2025 |
Common Stock |
8,650 |
$33.63 |
Direct |
F1, F11 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: